Aktis Oncology, Inc. (AKTS)

Aktis Oncology Statistics

Total Valuation

Aktis Oncology has a market cap or net worth of $1.08 billion. The enterprise value is $553.77 million.

Market Cap	1.08B
Enterprise Value	553.77M

Important Dates

The last earnings date was Monday, May 11, 2026, after market close.

Earnings Date	May 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Aktis Oncology has 55.28 million shares outstanding. The number of shares has increased by 1,784.33% in one year.

Current Share Class	53.40M
Shares Outstanding	55.28M
Shares Change (YoY)	+1,784.33%
Shares Change (QoQ)	+5,750.69%
Owned by Insiders (%)	0.46%
Owned by Institutions (%)	43.99%
Float	28.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	130.56
Forward PS	53.99
PB Ratio	2.14
P/TBV Ratio	2.14
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	66.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 19.49, with a Debt / Equity ratio of 0.02.

Current Ratio	19.49
Quick Ratio	19.37
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-14.44%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	$104,772
Profits Per Employee	-$849,000
Employee Count	79
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	18.70
200-Day Moving Average	n/a
Relative Strength Index (RSI)	52.42
Average Volume (20 Days)	199,594

Short Selling Information

The latest short interest is 2.57 million, so 4.65% of the outstanding shares have been sold short.

Short Interest	2.57M
Short Previous Month	2.34M
Short % of Shares Out	4.65%
Short % of Float	9.13%
Short Ratio (days to cover)	8.06

Income Statement

In the last 12 months, Aktis Oncology had revenue of $8.28 million and -$67.07 million in losses. Loss per share was -$5.25.

Revenue	8.28M
Gross Profit	-63.35M
Operating Income	-79.25M
Pretax Income	-67.07M
Net Income	-67.07M
EBITDA	-76.75M
EBIT	-79.25M
Loss Per Share	-$5.25

Balance Sheet

The company has $538.48 million in cash and $11.58 million in debt, with a net cash position of $526.91 million or $9.53 per share.

Cash & Cash Equivalents	538.48M
Total Debt	11.58M
Net Cash	526.91M
Net Cash Per Share	$9.53
Equity (Book Value)	506.11M
Book Value Per Share	9.16
Working Capital	516.03M

Cash Flow

In the last 12 months, operating cash flow was -$70.89 million and capital expenditures -$9.55 million, giving a free cash flow of -$80.43 million.

Operating Cash Flow	-70.89M
Capital Expenditures	-9.55M
Depreciation & Amortization	2.50M
Net Borrowing	n/a
Free Cash Flow	-80.43M
FCF Per Share	-$1.46

Margins

Gross Margin	n/a
Operating Margin	-957.44%
Pretax Margin	-810.33%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Aktis Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,784.33%
Shareholder Yield	-1,784.33%
Earnings Yield	-6.21%
FCF Yield	-7.44%

Analyst Forecast

The average price target for Aktis Oncology is $32.25, which is 64.96% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$32.25
Price Target Difference	64.96%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	117.88%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Aktis Oncology has an Altman Z-Score of 8.88 and a Piotroski F-Score of 2.

Altman Z-Score	8.88
Piotroski F-Score	2